aller au contenu
Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance Aperçu de cet ouvrage
FermerAperçu de cet ouvrage
Vérifiant…

Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance

Auteur : Benjamin Bonavida
Éditeur : New York, NY : Springer, 2013.
Collection : Resistance to targeted anti-cancer therapeutics, v.2
Édition/format :   Livre électronique : Document : AnglaisVoir toutes les éditions et tous les formats
Base de données :WorldCat
Résumé :
The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops  Lire la suite...
Évaluation :

(pas encore évalué) 0 avec des critiques - Soyez le premier.

Sujets
Plus comme ceci

 

Trouver un exemplaire en ligne

Liens vers cet ouvrage

Trouver un exemplaire dans la bibliothèque

&AllPage.SpinnerRetrieving; Recherche de bibliothèques qui possèdent cet ouvrage...

Détails

Genre/forme : Electronic books
Type d’ouvrage : Document, Ressource Internet
Format : Ressource Internet, Fichier informatique
Tous les auteurs / collaborateurs : Benjamin Bonavida
ISBN : 9781461476542 1461476542 1461476534 9781461476535
Numéro OCLC : 857224719
Notes : Includes index.
Description : 1 online resource (xiii, 202 pages) : illustrations.
Contenu : Resistance to Anticancer Antibodies: From Mechanisms to Solutions / Lina Reslan, Charles Dumontet --
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence / Yangyang Wang, Francesco Sabbatino, Ling Yu --
Overcoming Resistance to Therapeutic Antibodies by Targeting Fc Receptors / Emily L. Williams, Sean H. Lim --
Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance / Francisco J. Hernandez-Ilizaliturri --
Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype / Benjamin Bonavida --
Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer / Zacharenia Saridaki, John Souglakos --
Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors / Peter Hersey, Stuart Gallagher --
Strategies to Overcome TRAIL Resistance in Cancer / Simone Fulda --
Unnatural Amino Acid Antibody Conjugates as Next Generation Biologics / Vaughn Smider --
Antibody-Drug Conjugates: Can Coupling Cytotoxicity and Specificity Overcome Therapeutic Resistance? / Penelope M. Drake, David Rabuka.
Titre de collection : Resistance to targeted anti-cancer therapeutics, v.2
Responsabilité : Benjamin Bonavida, editor.
Plus d’informations :

Résumé :

Resistance to Immunotherapeutic Antibodies in Cancer  Lire la suite...

Critiques

Critiques d’utilisateurs
Récupération des critiques de GoodReads...
Récuperation des critiques DOGObooks…

Tags

Soyez le premier.
Confirmez cette demande

Vous avez peut-être déjà demandé cet ouvrage. Veuillez sélectionner OK si vous voulez poursuivre avec cette demande quand même.

Données liées


<http://www.worldcat.org/oclc/857224719>
library:oclcnum"857224719"
library:placeOfPublication
rdf:typeschema:Book
rdf:typeschema:MediaObject
rdf:valueUnknown value: dct
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:datePublished"2013"
schema:description"The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance. Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs."
schema:exampleOfWork<http://worldcat.org/entity/work/id/1754943023>
schema:genre"Electronic books"
schema:inLanguage"en"
schema:isPartOf
schema:name"Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance"
schema:url<http://lib.myilibrary.com?id=517004>
schema:url
schema:url<http://site.ebrary.com/id/10743790>
schema:url<http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=622877>
schema:workExample
schema:workExample
schema:workExample
wdrs:describedby

Content-negotiable representations

Fermer la fenêtre

Veuillez vous identifier dans WorldCat 

Vous n’avez pas de compte? Vous pouvez facilement créer un compte gratuit.